SANOFI : Merial acquires two major equine health products from Bayer

- Acquisition broadens Merial's global equine health solutions -

Paris, France - December 17, 2014 - Sanofi today announced that Merial, its animal health company, has reached an agreement with Bayer HealthCare to purchase two Bayer equine health products, Legend®/Hyonate® (hyaluronate sodium) and Marquis® (ponazuril).

Legend/Hyonate is an injectable solution that treats noninfectious joint dysfunction in horses; and Marquis Antiprotozoal Oral Paste is the first FDA-approved treatment for equine protozoal myeloencephalitis (EPM), a disease that affects the central nervous system in horses.

"We are pleased to add two top equine products to our global portfolio. Legend and Marquis are highly regarded by the horse community and further support our commitment to equine veterinarians, horse owners and trainers," said Merial CEO and Sanofi EVP Carsten Hellmann. "This addition is one example of our strategy to invest in business opportunities that enable us to deliver innovative solutions to veterinarians across animal species."

The purchase, expected to be finalized in early 2015, further broadens Merial's portfolio of leading products that improve the health and performance of horses. Legend/Hyonate is primarily sold in the US and Canada, but is available in more than 40 countries with the UK and Japan as important markets. Marquis is only sold in the US and Canada. Merial plans to make both products available to veterinarians in countries around the world. The acquisition is subject to customary closing conditions.

Merial is a global leader in advancing the health of pets, horses and production animals. The company's global equine portfolio currently includes products to treat and prevent Equine Gastric Ulcer Syndrome and to control parasites in horses, as well as vaccines to help prevent Equine West Nile Virus, Potomac Horse Fever, equine influenza, and rabies in horses. In October 2014, Merial launched its latest equine addition, with the EU approval of the updated equine influenza vaccine ProteqFlu®.

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs around 6,200 people and operates in more than 150 countries worldwide with more than to €2 billion of sales. Merial is a Sanofi company. www.merial.com

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

1/2

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes
that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward- looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidat es as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December
31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Laurence Bollack

+33 (0)1 53 77 46 46 mr@sanofi.com

Sébastien Martel

+33 (0)1 53 77 45 45 ir@sanofi.com

Heidi De Wit-Sommerfeld

+1 678 638 3763

heidi.dewit-sommerfeld@merial.com

2/2

distributed by